Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Why there's no Emgality equality

April 15, 2019

AUT-00206 reduces ketamine-induced BOLD response in phase Ib study

April 12, 2019

Autophagy disruption affects social behavior in mice

April 12, 2019

Pragma Therapeutics discovers mGlu7 receptor antagonists

April 12, 2019

Merck & Co. identifies new nicotinic alpha-7 receptor positive allosteric modulators

April 11, 2019

New model to trial schizophrenia preventative treatments

April 11, 2019

Dual kappa/delta-opioid agonist CA-1001 shows efficacy in pain models

April 10, 2019

Discovery and characterization of selective AMPAR/gamma-8 negative modulators as antiepileptics

April 10, 2019

Amyloid plaques age oligodendrocyte precursors

April 9, 2019

Arresting the transition from acute to chronic pain

April 8, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.